Abstract
Estrogen replacement therapy at accepted doses is not fully effective in preventing bone loss and fractures in postmenopausal women. Bone densitometry is useful for monitoring estrogen replacement therapy to assess dose, foster compliance, and check for secondary bone loss. The most appropriate site for bone loss monitoring is probably the spine because it shows larger decreases at the menopause than appendicular sites, it shows larger increases with therapy, and it has clinical import in terms of fracture. Both dual-photon absorptiometry (or dual-energy x-ray absorptiometry) and computed tomography are the preferred monitoring methods. The precision of these densitometry methods is generally adequate to permit interim decisions with regard to continuing therapy, as well as conclusive decisions on therapeutic efficacy after 1 to 2 years of monitoring. Judicious use of densitometry in combination with biochemical determinations can enhance therapeutic control and provide both patient and physician confidence in long-term estrogen replacement therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 843-848 |
| Number of pages | 6 |
| Journal | American Journal of Obstetrics and Gynecology |
| Volume | 161 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1989 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
- Obstetrics and Gynecology
Cite this
Monitoring skeletal response to estrogen. / Mazess, Richard B.; Gallagher, John Christopher G.; Notelovitz, Morris; Schiff, Isaac; Utian, Wulf.
In: American Journal of Obstetrics and Gynecology, Vol. 161, No. 4, 1989, p. 843-848.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Monitoring skeletal response to estrogen
AU - Mazess, Richard B.
AU - Gallagher, John Christopher G.
AU - Notelovitz, Morris
AU - Schiff, Isaac
AU - Utian, Wulf
PY - 1989
Y1 - 1989
N2 - Estrogen replacement therapy at accepted doses is not fully effective in preventing bone loss and fractures in postmenopausal women. Bone densitometry is useful for monitoring estrogen replacement therapy to assess dose, foster compliance, and check for secondary bone loss. The most appropriate site for bone loss monitoring is probably the spine because it shows larger decreases at the menopause than appendicular sites, it shows larger increases with therapy, and it has clinical import in terms of fracture. Both dual-photon absorptiometry (or dual-energy x-ray absorptiometry) and computed tomography are the preferred monitoring methods. The precision of these densitometry methods is generally adequate to permit interim decisions with regard to continuing therapy, as well as conclusive decisions on therapeutic efficacy after 1 to 2 years of monitoring. Judicious use of densitometry in combination with biochemical determinations can enhance therapeutic control and provide both patient and physician confidence in long-term estrogen replacement therapy.
AB - Estrogen replacement therapy at accepted doses is not fully effective in preventing bone loss and fractures in postmenopausal women. Bone densitometry is useful for monitoring estrogen replacement therapy to assess dose, foster compliance, and check for secondary bone loss. The most appropriate site for bone loss monitoring is probably the spine because it shows larger decreases at the menopause than appendicular sites, it shows larger increases with therapy, and it has clinical import in terms of fracture. Both dual-photon absorptiometry (or dual-energy x-ray absorptiometry) and computed tomography are the preferred monitoring methods. The precision of these densitometry methods is generally adequate to permit interim decisions with regard to continuing therapy, as well as conclusive decisions on therapeutic efficacy after 1 to 2 years of monitoring. Judicious use of densitometry in combination with biochemical determinations can enhance therapeutic control and provide both patient and physician confidence in long-term estrogen replacement therapy.
UR - http://www.scopus.com/inward/record.url?scp=0024452063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024452063&partnerID=8YFLogxK
U2 - 10.1016/0002-9378(89)90732-1
DO - 10.1016/0002-9378(89)90732-1
M3 - Article
C2 - 2679103
AN - SCOPUS:0024452063
VL - 161
SP - 843
EP - 848
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
SN - 0002-9378
IS - 4
ER -